European Archives - Page 644 of 1060 - European Medical Journal

Continue
2 Mins
12 Nov 2019

A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Nonresectable or Metastatic Soft Tissue Sarcomas Who are Not Candidates for Chemotherapy

Patients with metastatic soft tissue sarcoma (STS) have a poor prognosis with a median survival of 12–14 months.1 First-line therapy consists…
3 Mins
12 Nov 2019

Balancing the Scales: The Fight for Female Representation in Oncology

As exciting and momentous as the progression in medical oncology continues to be, a different type of progression is still sorely needed across…
2 Mins
12 Nov 2019

The Mutational Signature of Spontaneously Developing Tumours in MLH1-/- Mice - Potential Consequences for Immunotherapeutic Approaches

Mismatch repair-deficient (MMR-D) tumours exemplify the prototypic hypermutator phenotype. Owing to the high mutation rates, many neo-antigens…
3 Mins
12 Nov 2019

Epithelial Myoepithelial Carcinoma of the Hard Palate: A Case Report with a Review of the Literature

Epithelial myoepithelial carcinoma (EMC) was initially described by Donath et al…
1 Mins
12 Nov 2019

The 2016-2019 ImmunoTOX Assessment Board Report: Results from a Descriptive Real-Life Study of a Collaborative Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

Although immunotherapy is better tolerated globally than chemotherapy, immune checkpoint inhibitors may be associated with immune-related…
8 Mins
12 Nov 2019

PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer

Physiologically, cells are equipped with DNA damage repair systems that can correct various errors…
3 Mins
12 Nov 2019

Branchial Cleft Cyst – A Misdiagnosed Developmental Anomaly

The branchial cleft’s embryological journey begins between the first 3–8 weeks of intrauterine life. Five mesodermal arches form by the inpouching…
2 Mins
12 Nov 2019

Measuring the Cancer Burden in Europe: the European Cancer Information System (ECIS)

Cancer is the second leading cause of mortality in European Union (EU) Member States,1 with more than 1.4 million deaths…
1 Mins
12 Nov 2019

Phase I Combination Dose-Finding and Phase II Expansion Cohorts of Lenvatinib with Etoposide and Ifosfamide in Patients Aged 2 to ≤25 Years with Relapsed or Refractory Osteosarcoma

Osteosarcoma is the most common primary bone tumour in adolescents and young adults, with no survival improvement in the last few decades…
9 Mins
12 Nov 2019

Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS

The drug neratinib (HKI-272, Nerlynx®) was originally developed by Wyeth Research Laboratories, with its initial characterisation published in 2004…